Weihao Shao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Weihao Shao has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Caifang Zheng
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan, 450001, People’s Republic of China
4 shared publications- Weidong Zhang
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan, China
4 shared publications Bowen Zhang
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan, 450001, People’s Republic of China
3 shared publicationsGaili Wang
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan, 450001, People’s Republic of China
3 shared publicationsXiaorui Chen
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan, 450001, People’s Republic of China
3 shared publications- Bowen Zhang
School of Ecology and Environment, Zhengzhou University, Zhengzhou 450001, China
1 shared publication
Latest Publications
- Open Access
- 22 January 2026
- Published by Korean Endocrine Society in Endocrinology and Metabolism
Association between the Chinese Visceral Adiposity Index and Multimorbidity in Middle-Aged and Older Chinese Adults: A Prospective Cohort Study
Background: The association between visceral adiposity and multimorbidity in Chinese middle-aged and older adults remains underexplored. This study used data from the China Health and Retirement Longitudinal Study (CHARLS) to examine the relationship between visceral adiposity, measured by the Chinese visceral adiposity index (CVAI), and multimorbidity. Methods: This prospective cohort study analyzed data from 6,410 participants who were multimorbidity-free in the 2015 CHARLS wave, with follow-up assessments in 2018 and 2020. CVAI was calculated using age, body mass index, waist circumference, triglycerides, and high-density lipoprotein cholesterol. Latent class analysis (LCA) identified multimorbidity patterns, defined as the presence of ≥2 chronic conditions based on self-reported physician diagnoses. Cox regression and restricted cubic spline (RCS) analyses assessed the impact of CVAI on multimorbidity risk. Results: Over a median 5.0-year follow-up (interquartile range [IQR], 3.0 to 5.0), 2,809 participants (43.8%) developed multimorbidity. Each IQR increase in CVAI significantly elevated the risk of multimorbidity (hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.16 to 1.24). Higher risks were observed in the second (HR, 1.16; 95% CI, 1.04 to 1.30), third (HR, 1.28; 95% CI, 1.14 to 1.43), and fourth (HR, 1.76; 95% CI, 1.58 to 1.96) quartiles compared with the first. The RCS analysis demonstrated a dose-response relationship (Pnonlinearity=0.109). LCA identified four multimorbidity clusters. CVAI increments were significantly associated with the cardio-metabolic cluster (HR, 1.51; 95% CI, 1.42 to 1.62) and the arthritis-renal cluster (HR, 1.29; 95% CI, 1.21 to 1.39). Conclusion: Elevated CVAI is a strong risk factor for incident multimorbidity among middle-aged and older Chinese adults, emphasizing its importance in the development of distinct disease clusters.
- 22 January 2026
- Published by Korean Endocrine Society in Endocrinology and Metabolism
Open AccessAssociation between the Chinese Visceral Adiposity Index and Multimorbidity in Middle-Aged and Older Chinese Adults: A Prospective Cohort Study
Background: The association between visceral adiposity and multimorbidity in Chinese middle-aged and older adults remains underexplored. This study used data from the China Health and Retirement Longitudinal Study (CHARLS) to examine the relationship between visceral adiposity, measured by the Chinese visceral adiposity index (CVAI), and multimorbidity. Methods: This prospective cohort study analyzed data from 6,410 participants who were multimorbidity-free in the 2015 CHARLS wave, with follow-up assessments in 2018 and 2020. CVAI was calculated using age, body mass index, waist circumference, triglycerides, and high-density lipoprotein cholesterol. Latent class analysis (LCA) identified multimorbidity patterns, defined as the presence of ≥2 chronic conditions based on self-reported physician diagnoses. Cox regression and restricted cubic spline (RCS) analyses assessed the impact of CVAI on multimorbidity risk. Results: Over a median 5.0-year follow-up (interquartile range [IQR], 3.0 to 5.0), 2,809 participants (43.8%) developed multimorbidity. Each IQR increase in CVAI significantly elevated the risk of multimorbidity (hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.16 to 1.24). Higher risks were observed in the second (HR, 1.16; 95% CI, 1.04 to 1.30), third (HR, 1.28; 95% CI, 1.14 to 1.43), and fourth (HR, 1.76; 95% CI, 1.58 to 1.96) quartiles compared with the first. The RCS analysis demonstrated a dose-response relationship (Pnonlinearity=0.109). LCA identified four multimorbidity clusters. CVAI increments were significantly associated with the cardio-metabolic cluster (HR, 1.51; 95% CI, 1.42 to 1.62) and the arthritis-renal cluster (HR, 1.29; 95% CI, 1.21 to 1.39). Conclusion: Elevated CVAI is a strong risk factor for incident multimorbidity among middle-aged and older Chinese adults, emphasizing its importance in the development of distinct disease clusters.
- Open Access
- 1 November 2023
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 15, 1041-1053
Efficacy and Safety of Novel Oral Antivirals in Hospitalized COVID-19 Patients: A Network Meta-Analysis of Randomized Clinical Trials
Objective: Numerous pharmacological interventions are now under investigation for the treatment of the 2019 coronavirus pandemic (COVID-19), and the evidence is rapidly evolving. Our aim is to evaluate the comparative efficacy and safety of these drugs. Methods: We searched for randomized clinical trials (RCTs) on the efficacy and safety of novel oral antivirals for the treatment of hospitalized COVID-19 patients until November 30, 2022, including baricitinib, ivermectin (IVM), favipiravir (FVP), chloroquine (CQ), lopinavir and ritonavir (LPV/RTV), hydroxychloroquine (HCQ), and hydroxychloroquine plus azithromycin (HCQ+AZT). The main outcomes of this network meta-analysis (NMA) were in-hospital mortality, adverse event (AE), recovery time, and improvement in peripheral capillary oxygen saturation (SpO2). For dichotomous results, the odds ratio (OR) was used, and the 95% confidence interval (CI) was determined. We also used meta-regression to explore whether different treatments affected efficacy and safety. STATA 15.0 was used to conduct the NMA. The research protocol was registered with PROSPERO (#CRD 42023415743). Results: Thirty-six RCTs, with 33,555 hospitalized COVID-19 patients, were included in this analysis. First, we compared the efficacy of different novel oral antivirals. Baricitinib (OR 0.56, 95% CI: 0.35 to 0.90) showed the highest probability of being the optimal probiotic species in reducing in-hospital mortality and suggested that none of the interventions reduced AE better than placebo. In terms of safety outcomes, IVM ranked first in improving the recovery time of hospitalized COVID-19 patients (mean difference (MD) − 1.36, 95% CI: − 2.32 to − 0.39). In addition, patients were most likely to increase SpO2 (OR 1.77, 95% CI: 0.09 to 3.45). The meta-regression revealed no significant differences between participants using different novel oral antivirals in all outcomes in hospitalized COVID-19 patients. Conclusion: Currently, baricitinib has reduced in-hospital mortality in hospitalized COVID-19 patients, with moderate certainty of evidence. IVM appeared to be a safer option than placebo in improving recovery time, while FVP was associated with increased SpO2 safety outcomes. These preliminary evidence-based observations should guide clinical practice until more data are made public.
- 1 November 2023
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 15, 1041-1053
Open AccessEfficacy and Safety of Novel Oral Antivirals in Hospitalized COVID-19 Patients: A Network Meta-Analysis of Randomized Clinical Trials
Objective: Numerous pharmacological interventions are now under investigation for the treatment of the 2019 coronavirus pandemic (COVID-19), and the evidence is rapidly evolving. Our aim is to evaluate the comparative efficacy and safety of these drugs. Methods: We searched for randomized clinical trials (RCTs) on the efficacy and safety of novel oral antivirals for the treatment of hospitalized COVID-19 patients until November 30, 2022, including baricitinib, ivermectin (IVM), favipiravir (FVP), chloroquine (CQ), lopinavir and ritonavir (LPV/RTV), hydroxychloroquine (HCQ), and hydroxychloroquine plus azithromycin (HCQ+AZT). The main outcomes of this network meta-analysis (NMA) were in-hospital mortality, adverse event (AE), recovery time, and improvement in peripheral capillary oxygen saturation (SpO2). For dichotomous results, the odds ratio (OR) was used, and the 95% confidence interval (CI) was determined. We also used meta-regression to explore whether different treatments affected efficacy and safety. STATA 15.0 was used to conduct the NMA. The research protocol was registered with PROSPERO (#CRD 42023415743). Results: Thirty-six RCTs, with 33,555 hospitalized COVID-19 patients, were included in this analysis. First, we compared the efficacy of different novel oral antivirals. Baricitinib (OR 0.56, 95% CI: 0.35 to 0.90) showed the highest probability of being the optimal probiotic species in reducing in-hospital mortality and suggested that none of the interventions reduced AE better than placebo. In terms of safety outcomes, IVM ranked first in improving the recovery time of hospitalized COVID-19 patients (mean difference (MD) − 1.36, 95% CI: − 2.32 to − 0.39). In addition, patients were most likely to increase SpO2 (OR 1.77, 95% CI: 0.09 to 3.45). The meta-regression revealed no significant differences between participants using different novel oral antivirals in all outcomes in hospitalized COVID-19 patients. Conclusion: Currently, baricitinib has reduced in-hospital mortality in hospitalized COVID-19 patients, with moderate certainty of evidence. IVM appeared to be a safer option than placebo in improving recovery time, while FVP was associated with increased SpO2 safety outcomes. These preliminary evidence-based observations should guide clinical practice until more data are made public.
- Open Access
- 1 March 2023
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 15, 289-297
The Mediating Role of Body Mass Index in the Association Between Age at First Childbirth and Lung Function Among Chinese Postmenopausal Women
Objective: Little is known about the effect of age at first childbirth on lung function. We aimed to investigate the association between age at first childbirth and lung function in Chinese women and further test whether this association is mediated by body mass index (BMI). Methods: This cross-sectional study is a partial survey of the China Kadoorie Biobank (CKB) which was conducted in Xinxiang City, Henan Province between 2004 and 2008. A total of 16,584 postmenopausal women aged 30– 79 years were enrolled. Multiple linear and logistic regression were used to investigate the association between age at first childbirth and lung function and overweight/obesity. The mediation analysis was performed using the PROCESS procedure for SPSS. Results: The mean (SD) age at first childbirth was 23.1 (2.7) years. Women with first childbirth aged ≤ 19 years and 20– 22 years had lower lung function than women who gave first childbirth aged 23– 25 years. Per 1-year increase in the age at first childbirth was associated with a 3.31 mL increase in FEV1 (95% CI = 1.27– 5.35), 3.91 mL increase in FVC (95% CI = 1.63– 6.18), 0.15% increase in FEV1, % predicted (95% CI = 0.05– 0.24) and 0.14% increase in FVC, % predicted (95% CI = 0.05– 0.22). There was no clear association between age at first childbirth and FEV1/FVC ratio. BMI played a contribution to the association between age at first childbirth and FEV1 and the proportion was 16.4% (indirect effect: β = 0.65, 95% CI = 0.46– 0.89; total effect: β = 3.96, 95% CI = 1.92– 5.99). Similarly, the proportion to FVC, FEV1, % predicted, and FVC, % predicted was 25.0%, 16.6%, and 25.0%, respectively. Conclusion: Early age at first childbirth was associated with lower lung function and BMI mediated the association. It is important to test lung function and popularize the knowledge of weight control in women who gave first childbirth at an early age.
- 1 March 2023
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 15, 289-297
Open AccessThe Mediating Role of Body Mass Index in the Association Between Age at First Childbirth and Lung Function Among Chinese Postmenopausal Women
Objective: Little is known about the effect of age at first childbirth on lung function. We aimed to investigate the association between age at first childbirth and lung function in Chinese women and further test whether this association is mediated by body mass index (BMI). Methods: This cross-sectional study is a partial survey of the China Kadoorie Biobank (CKB) which was conducted in Xinxiang City, Henan Province between 2004 and 2008. A total of 16,584 postmenopausal women aged 30– 79 years were enrolled. Multiple linear and logistic regression were used to investigate the association between age at first childbirth and lung function and overweight/obesity. The mediation analysis was performed using the PROCESS procedure for SPSS. Results: The mean (SD) age at first childbirth was 23.1 (2.7) years. Women with first childbirth aged ≤ 19 years and 20– 22 years had lower lung function than women who gave first childbirth aged 23– 25 years. Per 1-year increase in the age at first childbirth was associated with a 3.31 mL increase in FEV1 (95% CI = 1.27– 5.35), 3.91 mL increase in FVC (95% CI = 1.63– 6.18), 0.15% increase in FEV1, % predicted (95% CI = 0.05– 0.24) and 0.14% increase in FVC, % predicted (95% CI = 0.05– 0.22). There was no clear association between age at first childbirth and FEV1/FVC ratio. BMI played a contribution to the association between age at first childbirth and FEV1 and the proportion was 16.4% (indirect effect: β = 0.65, 95% CI = 0.46– 0.89; total effect: β = 3.96, 95% CI = 1.92– 5.99). Similarly, the proportion to FVC, FEV1, % predicted, and FVC, % predicted was 25.0%, 16.6%, and 25.0%, respectively. Conclusion: Early age at first childbirth was associated with lower lung function and BMI mediated the association. It is important to test lung function and popularize the knowledge of weight control in women who gave first childbirth at an early age.
- Open Access
- 2 January 2023
- Published by Taylor & Francis in Annals of Human Biology
- Vol. 50 (1) , 127-136
Age at menarche and its association with blood pressure in adult women of developing countries: a systematic review and meta-analysis
Evidence about the effect of age at menarche (AAM) on blood pressure (BP) has largely been drawn from studies in developed countries. Studies in developing countries are expanding recently but have...
- 2 January 2023
- Published by Taylor & Francis in Annals of Human Biology
- Vol. 50 (1) , 127-136
Open AccessAge at menarche and its association with blood pressure in adult women of developing countries: a systematic review and meta-analysis
Evidence about the effect of age at menarche (AAM) on blood pressure (BP) has largely been drawn from studies in developed countries. Studies in developing countries are expanding recently but have...
- Open Access
- 29 September 2022
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 11 (1) , 2383-2392
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis
Knowing vaccine effectiveness (VE) against variants of concern (VOCs) in the real-world setting is essential for public health decision-making. A systematic landscape of the VE against a series of clinical outcomes caused by the VOCs in the real-world setting is needed. We systematically searched for studies that evaluated VE against VOCs in the real-world setting and collected individual data. We identified 113 studies meeting the eligibility criteria. We found full vaccination provided strong protection against each clinical outcome with summary VE ranging from 86.8% to 96.0% Alpha, moderate protection against infection caused by Beta, Gamma and Delta with summary VE ranging from 70.9% to 72.8%, strong protection against severe disease caused by Delta with summary VE ranging from 84.9% to 90.3%, limited protection with summary VE of 23.5% (95% CI, 17.0-29.5) against infection and moderate protection with summary VE ranging from 56.5% to 82.4% against severe diseases caused by Omicron. Booster vaccination can provide a substantial improvement in protection against Delta and Omicron, but not as much as the Delta. The meta-regression analysis showed that the VE against the Omicron wanned over time, and the VE against hospitalization declined relatively slowly compared to against infection. Those findings supported the need for public health measures, increasing booster vaccination coverage in response to current and new infectious waves driven by variants and developing broadly protective vaccines to confront virus evolution.
- 29 September 2022
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 11 (1) , 2383-2392
Open AccessEffectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis
Knowing vaccine effectiveness (VE) against variants of concern (VOCs) in the real-world setting is essential for public health decision-making. A systematic landscape of the VE against a series of clinical outcomes caused by the VOCs in the real-world setting is needed. We systematically searched for studies that evaluated VE against VOCs in the real-world setting and collected individual data. We identified 113 studies meeting the eligibility criteria. We found full vaccination provided strong protection against each clinical outcome with summary VE ranging from 86.8% to 96.0% Alpha, moderate protection against infection caused by Beta, Gamma and Delta with summary VE ranging from 70.9% to 72.8%, strong protection against severe disease caused by Delta with summary VE ranging from 84.9% to 90.3%, limited protection with summary VE of 23.5% (95% CI, 17.0-29.5) against infection and moderate protection with summary VE ranging from 56.5% to 82.4% against severe diseases caused by Omicron. Booster vaccination can provide a substantial improvement in protection against Delta and Omicron, but not as much as the Delta. The meta-regression analysis showed that the VE against the Omicron wanned over time, and the VE against hospitalization declined relatively slowly compared to against infection. Those findings supported the need for public health measures, increasing booster vaccination coverage in response to current and new infectious waves driven by variants and developing broadly protective vaccines to confront virus evolution.
- Open Access
- 13 January 2022
- Published by Springer Nature in Sleep and Biological Rhythms
- Vol. 20 (3) , 337-344
Association between sleep status and lower urinary tract symptoms among men aged 40 or older in Zhengzhou
A cross-sectional study based on the community was conducted to explore the association between sleep status and LUTS among middle and old-aged men. Male residents in Zhengzhou aged 40 or older were recruited. Participants received the Pittsburgh Sleep Quality Index questionnaire and the International Prostate Symptom Score questionnaire to evaluate sleep status and the severity of lower urinary tract symptoms (LUTS), respectively. Logistic regression analyses and linear regression analyses were performed to evaluate the relationship between sleep quality and sleep duration and LUTS. A total of 5785 participants were enrolled. Multivariable analyses showed a positive relationship between sleep quality and LUTS (β 0.716, 95% CI 0.647–0.784), and poor sleepers were significantly associated with moderate or severe LUTS (OR 2.486, 95% CI 2.095–2.950). U-shaped dose–response relationship revealed that sleeping less than 5.8 h/day and more than 7.9 h/day was related to moderate or severe LUTS and more than 7.9 h/day of sleep duration was associated with poor voiding and storage symptoms (P for nonlinearity < 0.001). Similar relationship was observed between sleep status and nocturia. It showed a significantly positive relationship between sleep quality and LUTS. U-shaped dose–response relationships between sleep duration and LUTS were observed.
- 13 January 2022
- Published by Springer Nature in Sleep and Biological Rhythms
- Vol. 20 (3) , 337-344
Open AccessAssociation between sleep status and lower urinary tract symptoms among men aged 40 or older in Zhengzhou
A cross-sectional study based on the community was conducted to explore the association between sleep status and LUTS among middle and old-aged men. Male residents in Zhengzhou aged 40 or older were recruited. Participants received the Pittsburgh Sleep Quality Index questionnaire and the International Prostate Symptom Score questionnaire to evaluate sleep status and the severity of lower urinary tract symptoms (LUTS), respectively. Logistic regression analyses and linear regression analyses were performed to evaluate the relationship between sleep quality and sleep duration and LUTS. A total of 5785 participants were enrolled. Multivariable analyses showed a positive relationship between sleep quality and LUTS (β 0.716, 95% CI 0.647–0.784), and poor sleepers were significantly associated with moderate or severe LUTS (OR 2.486, 95% CI 2.095–2.950). U-shaped dose–response relationship revealed that sleeping less than 5.8 h/day and more than 7.9 h/day was related to moderate or severe LUTS and more than 7.9 h/day of sleep duration was associated with poor voiding and storage symptoms (P for nonlinearity < 0.001). Similar relationship was observed between sleep status and nocturia. It showed a significantly positive relationship between sleep quality and LUTS. U-shaped dose–response relationships between sleep duration and LUTS were observed.